Unlock this StockReport nowClick to Unlock

American Cryostem Share Price

CRYO $0.58 0.0  0.0%

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary

FINANCIAL BRIEF: For the fiscal year ended 30 September 2018, American Cryostem Corp revenues decreased 41% to $1.1M. Net loss increased 22% to $1.5M. Revenues reflect Tissue storage & processing decrease of 58% to $571K, Consulting fees decrease of 75% to $75K, Product sales decrease of 89% to $8K. Higher net loss reflects Research & development increase from $87K to $342K (expense), Professional fees increase from $73K to $172K (expense). more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 30th Sep '18) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
30th Sep 2019
30th Sep 2020

Price Target: N/A
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a () () () () () ()
Consensus Estimate
1m Change
3m Change
Broker Consensus Trend
Broker Recommendations for American Cryostem
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts:

Named Brokers and Analysts
There are no named brokers.

Profile Summary

American CryoStem Corporation is a developer and marketer of adipose tissue-based cellular technologies and related services. The Company focuses on clinical processing, commercial bio-banking and application development for adipose (fat) tissue and autologous adipose-derived regenerative cells (ADRCs). The Company's products and services include CELLECT, ATGRAFT, ATCELL, ACSelerate, ACS Laboratories, Autokine-CM and International Licensing Program. The Company is in the business of collecting adipose tissue, processing it to separate the adult stem cells, and preparing such stem cells for long-term storage. Its ATGRAFT procedures include breast reconstruction, layered augmentation, buttocks enhancement or volume corrections of the hands, feet, face and neck areas. Its ACSelerate product is engaged in manufacturing various versions of its ACSelerate cell culture media, which includes ACSelerate-MAX, ACSelerate-SFM, ACSelerate-CY, ACSelerate-MY, ACSelerate-CP and ACSelerate-TR.

Directors: John Arnone (CHM) 59, Anthony Dudzinski (COO) 54, John DiFolco (EVP) 32,

No. of Employees: 6 No. of Shareholders: n/a

Last Annual September 30th, 2018
Last Interim September 30th, 2018
Incorporated March 13, 2009
Shares in Issue 48,854,043
Free Float 24.7m (50.5%)
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange OTC Markets Group
Eligible for an ISA? a SIPP?

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.

Should you buy CRYO

Access CRYO Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis